» Articles » PMID: 32093722

Systematic Review and Meta-analysis of the Prevalence of Chronic Fatigue Syndrome/myalgic Encephalomyelitis (CFS/ME)

Overview
Journal J Transl Med
Publisher Biomed Central
Date 2020 Feb 26
PMID 32093722
Citations 168
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) has been emerging as a significant health issue worldwide. This study aimed to systemically assess the prevalence of CFS/ME in various aspects of analyses for precise assessment.

Methods: We systematically searched prevalence of CFS/ME from public databases from 1980 to December 2018. Data were extracted according to 7 categories for analysis: study participants, gender and age of the participants, case definition, diagnostic method, publication year, and country of the study conducted. Prevalence data were collected and counted individually for studies adopted various case definitions. We analyzed and estimated prevalence rates in various angles: average prevalence, pooled prevalence and meta-analysis of all studies.

Results: A total of 1291 articles were initially identified, and 45 articles (46 studies, 56 prevalence data) were selected for this study. Total 1085,976 participants were enrolled from community-based survey (540,901) and primary care sites (545,075). The total average prevalence was 1.40 ± 1.57%, pooled prevalence 0.39%, and meta-analysis 0.68% [95% CI 0.48-0.97]. The prevalence rates were varied by enrolled participants (gender, study participants, and population group), case definitions and diagnostic methods. For example, in the meta-analysis; women (1.36% [95% CI 0.48-0.97]) vs. men (0.86% [95% CI 0.48-0.97]), community-based samples (0.76% [95% CI 0.53-1.10]) vs. primary care sites (0.63% [95% CI 0.37-1.10]), adults ≥ 18 years (0.65% [95% CI 0.43-0.99]) vs. children and adolescents < 18 years (0.55% [95% CI 0.22-1.35]), CDC-1994 (0.89% [95% CI 0.60-1.33]) vs. Holmes (0.17% [95% CI 0.06-0.49]), and interviews (1.14% [95% CI 0.76-1.72]) vs. physician diagnosis (0.09% [95% CI 0.05-0.13]), respectively.

Conclusions: This study comprehensively estimated the prevalence of CFS/ME; 0.89% according to the most commonly used case definition CDC-1994, with women approximately 1.5 to 2 folds higher than men in all categories. However, we observed the prevalence rates are widely varied particularly by case definitions and diagnostic methods. An objective diagnostic tool is urgently required for rigorous assessment of the prevalence of CFS/ME.

Citing Articles

Letter: Time to correct the record on the global burden of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS).

Vardaman M, Gilmour S J Transl Med. 2025; 23(1):331.

PMID: 40087760 DOI: 10.1186/s12967-025-06281-0.


Health-related quality of life in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome and Post COVID-19 Condition: a systematic review.

Weigel B, Inderyas M, Eaton-Fitch N, Thapaliya K, Marshall-Gradisnik S J Transl Med. 2025; 23(1):318.

PMID: 40075382 PMC: 11905571. DOI: 10.1186/s12967-025-06131-z.


mTORC1 syndrome (TorS): unifying paradigm for PASC, ME/CFS and PAIS.

Bar-Tana J J Transl Med. 2025; 23(1):297.

PMID: 40059164 PMC: 11892318. DOI: 10.1186/s12967-025-06220-z.


A network medicine approach to investigating ME/CFS pathogenesis in severely ill patients: a pilot study.

Hung L, Wu C, Chang C, Li P, Hicks K, Dibble J Front Hum Neurosci. 2025; 19:1509346.

PMID: 39996021 PMC: 11847890. DOI: 10.3389/fnhum.2025.1509346.


Efficacy and safety of Xiaoyao San in the treatment of chronic fatigue syndrome: a systematic review and meta-analysis.

Wang Q, Zhou J, Gong G Front Pharmacol. 2025; 16:1496774.

PMID: 39981187 PMC: 11839657. DOI: 10.3389/fphar.2025.1496774.


References
1.
Higgins J, Thompson S . Quantifying heterogeneity in a meta-analysis. Stat Med. 2002; 21(11):1539-58. DOI: 10.1002/sim.1186. View

2.
Huibers M, Kant I, Swaen G, Kasl S . Prevalence of chronic fatigue syndrome-like caseness in the working population: results from the Maastricht cohort study. Occup Environ Med. 2004; 61(5):464-6. PMC: 1740780. DOI: 10.1136/oem.2003.008912. View

3.
Evengard B, Jacks A, Pedersen N, Sullivan P . The epidemiology of chronic fatigue in the Swedish Twin Registry. Psychol Med. 2005; 35(9):1317-26. DOI: 10.1017/S0033291705005052. View

4.
Bayliss K, Riste L, Band R, Peters S, Wearden A, Lovell K . Implementing resources to support the diagnosis and management of Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/ME) in primary care: A qualitative study. BMC Fam Pract. 2016; 17:66. PMC: 4893302. DOI: 10.1186/s12875-016-0453-8. View

5.
Rimes K, Ashcroft J, Bryan L, Chalder T . Emotional suppression in chronic fatigue syndrome: Experimental study. Health Psychol. 2016; 35(9):979-86. DOI: 10.1037/hea0000341. View